Is ATRC or NAMS more profitable?

ATRC runs the higher net margin — ATRC at 1.85% versus NAMS at -3644.21%.

How have ATRC and NAMS total returns compared?

Over the past 5 years, ATRC delivered -4.06% and NAMS delivered 18.30% annualized total return. Past performance doesn't predict future results.

AtriCure, Inc. (ATRC) vs NewAmsterdam Pharma Company N.V. (NAMS)

A side-by-side comparison of AtriCure, Inc. and NewAmsterdam Pharma Company N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ATRC

AtriCure, Inc.

$2.78B

$54.73HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT

NAMS

NewAmsterdam Pharma Company N.V.

$2.63B

$22.52HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT

Total return — ATRC vs NAMS

growth of $100 · dividends reinvested · last 6y

ATRC -3.5% (-0.6%/yr)NAMS +114.9% (+13.6%/yr)NAMS compounded faster over this window

ATRC NAMS

ATRC vs NAMS: by the numbers

•ATRC is the larger company ($2.78B vs $2.63B market cap).
•ATRC is profitable (1.85% net margin) while NAMS runs a net loss (-3644.21%).

Metrics side by side

Valuation

Metric	ATRC	NAMS
P/E ratio	257.89	N/A
P/S ratio	4.89	369.62
P/B ratio	5.39	4.17
EV / EBITDA	77.33	N/A
FCF yield	1.84%	N/A

Profitability

Metric	ATRC	NAMS
Gross margin	76.16%	92.15%
Operating margin	2.44%	-1002.90%
Net margin	1.85%	-3644.21%
ROE	2.04%	-41.10%
ROIC	2.04%	-38.70%

Growth (annualized)

Metric	ATRC	NAMS
Revenue CAGR (5Y)	18.57%	N/A
Total return CAGR (5Y)	-4.06%	18.30%

Frequently asked

Is ATRC or NAMS more profitable?: ATRC runs the higher net margin — ATRC at 1.85% versus NAMS at -3644.21%.
How have ATRC and NAMS total returns compared?: Over the past 5 years, ATRC delivered -4.06% and NAMS delivered 18.30% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ATRC analysis Full NAMS analysis Interactive comparison tool

Dig into the metrics

AtriCure P/E ratio AtriCure ROE NewAmsterdam Pharma ROE AtriCure operating margin NewAmsterdam Pharma operating margin AtriCure revenue growth NewAmsterdam Pharma revenue growth AtriCure free cash flow NewAmsterdam Pharma free cash flow

AtriCure & NewAmsterdam Pharma appear in these rankings

Fastest Revenue Growth Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.